Scroll To Top
Health

Study shows switching from Zerit can improve lipoatrophy

Study shows switching from Zerit can improve lipoatrophy

We need your help
Your support makes The Advocate's original LGBTQ+ reporting possible. Become a member today to help us continue this work.

A study in the journal Clinical Infectious Diseases shows that switching HIV-positive people from a regimen containing Zerit (d4T) to one containing either Ziagen or Retrovir can result in significant improvements in lipoatrophy, the loss of body fat linked with the use of anti-HIV medications. After 48 weeks of being switched off regimens containing Zerit, study subjects had a median increase in arm fat of 35%, in leg fat of 12%, and in trunk fat of 18%. Facial fat measurements were not recorded, but a survey of the study subjects showed that 27% felt they had regained some fat in their faces, while 22% reported apparent fat gains in the arms, and 19% said they had more fat in the buttocks. The researchers conclude that replacing Zerit in an anti-HIV drug regimen can result in significant improvements in HIV-related lipoatrophy while continuing to suppress HIV replication. Previous studies have shown that after a median duration of 14 months, as many as 60% of HIV patients taking Zerit will experience fat loss. Other factors linked with lipoatrophy include duration of HIV disease, length of time on anti-HIV medications, older age, having had advanced HIV disease, and elevated triglyceride levels.

Point Foundation 2025 MorganOut / Advocate Magazine - Alan Cumming and Jake Shears

From our Sponsors

Most Popular

Latest Stories

Outtraveler Staff